The secondary leukemias: challenges and research directions.
about
MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25)Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemiaRisk definition and management strategies in retinoblastoma: current perspectivesBiomarkers of leukemia risk: benzene as a modelClinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia.Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots.Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocationMolecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemiaOncogenic resistance to growth-limiting conditions.Nutlin-3 enhances sorafenib efficacy in renal cell carcinomaLeukemias related to treatment with DNA topoisomerase II inhibitors.Malignancy: Tumor Suppressor Gene Aberrations in Acute Myelogenous Leukemia.Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia.The nature of chromosomal aberrations detected in humans exposed to benzene.Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells.Chromosomal translocations involving the MLL gene: molecular mechanisms.Causes of oncogenic chromosomal translocation.Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map.Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinomaEtoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia.Secondary hematological malignancies associated with temozolomide in patients with glioma.Sequence and structural basis for chromosomal fragility during translocations in cancer.The evolving landscape in the therapy of acute myeloid leukemia.A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases.DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosisAcute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells.A novel dual function retrovirus expressing multidrug resistance 1 and O6-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents.Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.Letter to the editor: acute myeloid leukemia in a patient surviving retinoblastoma.Genome-wide approach to identify risk factors for therapy-related myeloid leukemia.
P2860
Q22009898-B2579633-DD12-49DB-9DAD-BAA898F9A287Q24670279-D3CDABC4-7CD1-4A27-B962-AD4F90EFC270Q26849675-E1EB58E8-489B-442C-9F97-CB872943DD9AQ28390077-2CEC3739-EC37-4C06-AB7C-4C195DEB88ABQ30982315-382F9588-C224-481C-AD19-55E17246FB4CQ33737642-92A37B4D-8EBB-46BC-9C6E-919F619CF079Q33933823-BACB158B-A284-4483-A54E-C430705760D2Q33943185-FEBACA18-A7CF-4355-B1FA-D236BB6B5523Q34126792-BE3B4723-00CB-47B8-9048-59F416DFA26BQ34127380-D0A3412F-6FDA-4C35-9EE4-77B726D76AD3Q34243503-B9AC25BD-B1AA-41EC-983D-6E1F66AD4853Q34278271-2B44C1F2-5FF2-49F2-83C0-938466F549ECQ34380411-B373E266-B53B-4511-A4BE-89036DB1634AQ34532055-1F3D53F3-9527-4480-A9DF-135F21765CDAQ34534299-403EC9B9-558B-4606-A022-65DDD42A88C6Q35128590-A42BC8ED-0826-40B2-9D51-6B0AA9BC8071Q35570942-52324304-57D1-42F3-BDC4-FB14DB26F0AEQ36243996-CB8F5705-BE3E-4B2C-B930-2F3FE58B20CDQ36641844-6409234B-2B9C-4A6D-AC87-86AF26DCBBE0Q36973276-80B53FE9-3A32-45C7-A5DF-DCEEE65BD4B2Q37187672-7A42F0AD-6588-41E1-86EE-08A132155ED9Q38048886-D367F8DC-B421-4E7A-BAC6-98208B37897BQ38132064-6C88C404-914B-4B7F-B66C-83FE547BDD5AQ38259434-0CE730AE-5FDB-4534-9234-5689F1B6D2F4Q40022761-9B1F7E35-E316-4878-8C4C-C74310DA475CQ40470548-D0E4A18F-629C-4389-B66C-453E273BE280Q40799213-0045E6AA-FD7F-4CAB-B3A8-B565B72560E6Q41823310-90C8CAB7-2383-4F22-97FF-0BEA7708E32AQ43666936-7EE0E61B-F5D0-4646-996B-EF23A09C0B3CQ43976766-D9BB15F1-CB07-419E-B4F7-74BE12E8BE2CQ46845159-2D9031A3-C085-4B5F-97B1-0A9C6BE13165
P2860
The secondary leukemias: challenges and research directions.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
The secondary leukemias: challenges and research directions.
@en
type
label
The secondary leukemias: challenges and research directions.
@en
prefLabel
The secondary leukemias: challenges and research directions.
@en
P2093
P356
P1476
The secondary leukemias: challenges and research directions.
@en
P2093
P304
P356
10.1093/JNCI/88.7.407
P407
P577
1996-04-01T00:00:00Z